Evidence map›Paper›PMID 30344108›Full record

ArticleStructure (London, England : 1993)2019

Non-syndromic Mitral Valve Dysplasia Mutation Changes the Force Resilience and Interaction of Human Filamin A.

Tatu J K Haataja, Rafael C Bernardi, Simon Lecointe, Romain Capoulade, Jean Merot, Ulla Pentikäinen

Open access · bronzeAbstract read
In one paragraph

Article in Structure (London, England : 1993), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Mechanisms of mitral valve development and disease.Frontiers in cardiovascular medicine · 2026
    Review
  2. UltrastrongScience advances · 2025
    Article
  3. Article
  4. Structure and Function of Filamin C in the Muscle Z-Disc.International journal of molecular sciences · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Tatu J K HaatajaDepartment of Biological and Environmental Science and Nanoscience Center, University of Jyväskylä, 40014 Jyväskylä, Finland.
Rafael C BernardiBeckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Simon LecointeL'institut du Thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.
Romain CapouladeL'institut du Thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.
Jean MerotL'institut du Thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.
Ulla PentikäinenDepartment of Biological and Environmental Science and Nanoscience Center, University of Jyväskylä, 40014 Jyväskylä, Finland; Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA; Institute of Biomedicine, University of Turku, 20520 Turku, Finland; Turku Centre for Biotechnology, University of Turku, 20520 Turku, Finland. Electronic address: ulla.pentikainen@utu.fi.
Centre National de la Recherche Scientifique · FRUniversity of Illinois Urbana-Champaign · USUniversity of Jyväskylä · FIUniversity of Turku · FI

Funding

WHOLE CELL SIMULATIONP41GM104601 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI TAJKHORSHID, EMAD · 2012 to 2021
$19.0M
NIGMS NIH HHS P41 GM104601
6 · The paper itself

Abstract

Filamin A (FLNa), expressed in endocardial endothelia during fetal valve morphogenesis, is key in cardiac development. Missense mutations in FLNa cause non-syndromic mitral valve dysplasia (FLNA-MVD). Here, we aimed to reveal the currently unknown underlying molecular mechanism behind FLNA-MVD caused by the FLNa P637Q mutation. The solved crystal structure of the FLNa3-5 P637Q revealed that this mutation causes only minor structural changes close to mutation site. These changes were observed to significantly affect FLNa's ability to transmit cellular force and to interact with its binding partner. The performed steered molecular dynamics simulations showed that significantly lower forces are needed to split domains 4 and 5 in FLNA-MVD than with wild-type FLNa. The P637Q mutation was also observed to interfere with FLNa's interactions with the protein tyrosine phosphatase PTPN12. Our results provide a crucial step toward understanding the molecular bases behind FLNA-MVD, which is critical for the development of drug-based therapeutics.

Indexed as

Mutation, MissenseBinding SitesFilaminsHeart Valve DiseasesHumansMitral ValveMolecular Dynamics SimulationProtein BindingProtein Tyrosine Phosphatase, Non-Receptor Type 12FilaminsFLNA protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 12PTPN12 protein, humanFilamin AFLNA-MVDmechanical forcesmitral valve prolapseprotein tyrosine phosphatase 12steered molecular dynamics simulationsX-ray crystallography

Identifiers

PMID30344108
PMCPMC6984350
OpenAlexW2896152421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.